Aligos Therapeutics (ALGS) Insider Chavez Buys 5,860 Shares

Margarita Chavez, an insider at ALGS, recently bought 5,860 shares of the company on June 25, 2026. The transaction didn't have a disclosed price, and it wasn't part of a pre-planned trading program.

Insider Buying and Selling at Aligos Therapeutics, Inc.

On June 25, 2026, several insiders at ALGS, including Carole Nuechterlein, Margarita Chavez, Peter Hirth, Heather Preston, Bridget Martell, and James Paul Scopa, each acquired 5,860 shares. These transactions were not conducted under Rule 10b5-1 trading plans.

Other Institutional Activity in ALGS

Bank of America Corp substantially increased its position in ALGS, adding 216,646 shares to hold a total of 229,754 shares valued at about $1.71 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 178,262 shares worth approximately $1.32 million. On the other hand, SIO Capital Management, LLC reduced its holdings by 8,700 shares, bringing its total to 327,237 shares valued at $2.43 million.

Aligos Therapeutics, Inc. Stock Up 3.6%

Shares of ALGS traded near $5.57 on Tuesday. The company has attracted attention from institutional investors and analysts alike, with recent trades reflecting diverse strategies among major funds.

Analysts Set New Price Targets

On May 28, 2026, Lake Street initiated coverage on ALGS with a 'buy' rating and a $45 price target. A week earlier, on May 21, Cantor Fitzgerald also started coverage with a 'buy' rating and a $20 target. Additionally, WestPark Capital and Jefferies both initiated 'buy' ratings in March with targets of $48.

About ALGS

ALGS is a company primarily engaged in [describe business operations in a simple way]. The company is headquartered in [city, state], and it operates within the [sector/industry]. [Any additional information about leadership or employees if available].

Bottom Line

Margarita Chavez's recent purchase of ALGS shares is part of a broader pattern of insider buying at the company. Investors should note that this insider activity was not part of any pre-planned trading program. Institutional investors have shown varied strategies, with some increasing and others decreasing their stakes. Analysts have been optimistic, with several 'buy' ratings and price targets suggesting potential growth. As always, remember that insider and institutional activity is backward-looking and may not reflect current positions.